ReviewFrontiers in physiology2026
Cardiac biomarkers in athletes and active individuals: a clinical review of exercise-induced elevations and diagnostic interpretation.
Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exercise-induced increases in cardiac biomarkers, especially natriuretic peptides (B-type Natriuretic Peptide (BNP)/N-terminal (NT)-proBNP) and high-sensitivity troponin (hs-cTn), make it more difficult to distinguish between myocardial disease and physiological adaptation in athletes. The pathophysiology, release kinetics, and diagnostic performance of established biomarkers (hs-cTnI, hs-cTnT, BNP, NT-proBNP) and emerging candidates (galectin-3, ST2, GDF-15, heart-type fatty acid-binding protein, cardiac myosin-binding protein-C) are examined in this review. The main limitations include the lack of athlete-specific reference ranges (74-96% of marathon runners exceed standard hs-cTn thresholds), small sample sizes (most n<100), short follow-up, and varied exercise protocols. The assessment of acute cardiac stress, the distinction between an athlete's heart and cardiomyopathy, and the choice to return to play after myocarditis continue to be the principal clinical uses. Without thorough confirmation, claims like artificial intelligence-powered multi-omics, tailored molecular exercise prescription, and real-time monitoring remain theoretical. Sport-specific 99th percentiles, large prospective cohorts with 5-10-year follow-up, standardized methodologies, and verified point-of-care testing are all necessary for future priority. Until then, prolonged increases (>72 hours) or symptomatic presentations warrant further research, whereas exercise-induced biomarker elevations in asymptomatic athletes should be considered mostly benign and temporary.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.